Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

61.17 -0.14 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
 
Via Benzinga
Competitive Analysis In The ATTR-CM Field
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales. 
Via Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
 
Via Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts
 
Via Benzinga
Ionis Pharma Beats Expectations for Q4
The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss. 
Via The Motley Fool
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million. 
Via Benzinga
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025. 
Via Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
 
Via Benzinga
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
 
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
 
Via Benzinga
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
 
Via Benzinga
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
 
Via Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
 
Via Benzinga
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
The Latest Analyst Ratings For Ionis Pharmaceuticals
 
Via Benzinga
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.